Patents by Inventor John Strang

John Strang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VISUAL ROBOTIC TASK CONFIGURATION SYSTEM
    Publication number: 20260077505
    Abstract: The present disclosure relates generally to robotic systems, and more specifically to systems and methods for specifying a robot task configuration by means of annotating a visual workspace representation in coordination with a waypoint optimization process. This system enables a much broader use of robotic automation by saving time and reducing technical complexity. This system can be used to configure any visually enabled robotic task, such as tasks in warehouse management, manufacturing, delivery, inspection, logistics, etc.
    Type: Application
    Filed: September 5, 2023
    Publication date: March 19, 2026
    Applicant: Tutor Intelligence, Inc.
    Inventors: Joshua Aaron GRUENSTEIN, Alon Zechariah KOSOWSKY-SACHS, Zev MINSKY-PRIMUS, Moises TREJO, Tommy Seng HENG, Joshua FISHMAN, John STRANG
  • Intranasal pharmaceutical dosage forms comprising naloxone
    Patent number: 12458591
    Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
    Type: Grant
    Filed: September 19, 2023
    Date of Patent: November 4, 2025
    Assignee: HARM REDUCTION THERAPEUTICS, INC.
    Inventors: John Strang, Alexander Oksche, Stephen Harris, Kevin Smith, Lucie Helene Jeanne Mottier
  • INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE
    Publication number: 20240082149
    Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
    Type: Application
    Filed: September 19, 2023
    Publication date: March 14, 2024
    Inventors: John Strang, Alexander Oksche, Stephen Harris, Kevin Smith, Lucie Helene Jeanne Mottier
  • Intranasal pharmaceutical dosage forms comprising naloxone
    Patent number: 11806428
    Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: November 7, 2023
    Assignee: HARM REDUCTION THERAPEUTICS, INC.
    Inventors: John Strang, Alexander Oksche, Stephen Harris, Kevin Smith, Lucie Helene Jeanne Mottier
  • INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE
    Publication number: 20210338574
    Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
    Type: Application
    Filed: April 23, 2021
    Publication date: November 4, 2021
    Inventors: John Strang, Alexander Oksche, Stephen Harris, Kevin Smith, Lucie Helene Jeanne Mottier
  • Intranasal pharmaceutical dosage forms comprising naloxone
    Patent number: 11020343
    Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HC dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: June 1, 2021
    Assignee: Harm Reduction Therapeutics, Inc.
    Inventors: John Strang, Alexander Oksche, Stephen Harris, Kevin Smith, Lucie Helene Jeanne Mottier
  • INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE
    Publication number: 20190374464
    Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HC dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
    Type: Application
    Filed: August 23, 2019
    Publication date: December 12, 2019
    Inventors: John STRANG, Alexander OKSCHE, Stephen HARRIS, Kevin SMITH, Lucie Helene Jeanne MOTTIER
  • INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE
    Publication number: 20170304192
    Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
    Type: Application
    Filed: May 9, 2017
    Publication date: October 26, 2017
    Inventors: John STRANG, Alexander OKSCHE, Stephen HARRIS, Kevin SMITH, Lucie Helene Jeanne MOTTIER
  • Intranasal Pharmaceutical Dosage Forms Comprising Naloxone
    Publication number: 20170231904
    Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
    Type: Application
    Filed: January 27, 2017
    Publication date: August 17, 2017
    Inventors: John STRANG, Alexander OKSCHE, Stephen HARRIS, Kevin SMITH, Lucie Helene Jeanne MOTTIER
  • Intranasal Pharmaceutical Dosage Forms Comprising Naloxone
    Publication number: 20150126540
    Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
    Type: Application
    Filed: January 6, 2015
    Publication date: May 7, 2015
    Inventors: John STRANG, Alexander OKSCHE, Stephen HARRIS, Kevin SMITH, Lucie Helene Jeanne MOTTIER
  • Intranasal Pharmaceutical Dosage Forms Comprising Naloxone
    Publication number: 20150018379
    Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
    Type: Application
    Filed: May 11, 2012
    Publication date: January 15, 2015
    Applicant: Euro-Celtique S.A.
    Inventors: John Strang, Alexander Oksche, Stephen Harris, Kevin Smith, Lucie Helene Jeanne Mottier